Hypophosphatasia
4
Pipeline Programs
6
Companies
3
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
1
3
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
5 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
NovartisBPS804
AM-PharmaIlofotase Alfa, 0.8 mg/kg
CENTOGENEUnraveling Genetics of HypoPhosPhatasia (HPP Genetics)
Clinical Trials (3)
Total enrollment: 24 patients across 3 trials
Dose Escalation Study to Evaluate the Safety and Tolerability of Multiple Infusions of BPS804 in Adults With Hypophosphatasia (HPP)
Start: Jul 2011Est. completion: Sep 20128 patients
Phase 2Completed
Pilot Trial of Single Dose Ilofotase Alfa in Hypophosphatasia
Start: May 2023Est. completion: Jul 2023
Phase 1/2Completed
Unraveling Genetics of HypoPhosPhatasia (HPP Genetics)
Start: Jun 2021Est. completion: Dec 202116 patients
N/ACompleted
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
6 companies competing in this space